By Sheri Kasprzak
New York, April 28 - NicOx SA said it has completed a private placement for €45.52 million with a large group of international institutional investors.
The company sold 4,552,000 shares to 43 U.S.- and Europe-based institutional investors.
The offering represents 14.2% of the company's issued share capital.
The proceeds will be used for research and development on HCT 3012, the company's lead product for osteoarthritis.
Located in Sophia Antipolis, France, NicOx is a biopharmaceutical company focused on developing nitric oxide-donating drugs used to treat inflammatory and cardio-metabolic disorders.
| Issuer: | NicOx SA
|
| Issue: | Stock
|
| Amount: | €45.52 million
|
| Shares: | 4,552,000
|
| Price: | €10.00
|
| Warrants: | No
|
| Settlement date: | April 28
|
| Stock symbol: | Frankfurt: NXO
|
| Stock price: | €11.51 at close April 27
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
